Image de couverture de livre

Less frequent dosing of GLP‐1 receptor agonists as a viable weight maintenance strategy

Fuente: Wiley Open Access

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Calvin C. Wu, Anıl Cengiz, Sean D. Lawley
Format:	Artículo Open Access
Publié:	Wiley 2025
Sujets:	Obesity
Accès en ligne:	Acceder al recurso
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Incretin mimetics for weight loss forgive nonadherence
par: Anıl Cengiz, et autres
Publié: (2025)

Digital engagement enhances dual GIP / GLP ‐1 receptor agonist and GLP ‐1 receptor agonist efficacy: A retrospective cohort analysis of a digital weight loss service on outcomes and safety
par: Hans Johnson, et autres
Publié: (2025)

The extent and predictors of off‐label use of GLP ‐1 receptor agonists for weight loss management
par: Zbigniew Siudak, et autres
Publié: (2025)

Psychiatric effects of GLP ‐1 receptor agonists: A systematic review of emerging evidence
par: Brianna Sa, et autres
Publié: (2025)

GLP‐1 receptor agonists and retained gastric content: Is it much ado about nothing?
par: Michael Camilleri
Publié: (2025)

Balancing procedural safety and therapeutic continuity: GLP‐1 receptor agonists and upper endoscopy
par: Lien‐Chung Wei, et autres
Publié: (2025)

Healthcare professionals' perceptions and management of obesity & knowledge of glucagon, GLP‐1, GIP receptor agonists, and dual agonists
par: W. Timothy Garvey, et autres
Publié: (2024)

Highway to the danger zone? A cautionary account that GLP‐1 receptor agonists may be too effective for unmonitored weight loss
par: Jesse R. Richards, et autres
Publié: (2024)

GLP ‐1 receptor agonists and cardiovascular events in metabolically healthy or unhealthy obesity
par: Tommaso Bucci, et autres
Publié: (2025)

GLP ‐1 receptor agonists versus testosterone in male reproductive health: A critical perspective
par: João Oliveira Torres, et autres
Publié: (2025)

Safety, pharmacokinetics and pharmacodynamics of multiple‐dose noiiglutide ( SHR20004 ), a novel GLP ‐1 receptor agonist, in Chinese obese subjects without diabetes mellitus
par: Yang Zou, et autres
Publié: (2024)

Comparative healthcare resource utilization and costs of empagliflozin and GLP ‐1 receptor agonists in type 2 diabetes
par: Phyo Than Htoo, et autres
Publié: (2025)

Beyond diabetes and obesity: GLP ‐1 receptor agonists in disrupting the vicious cycle of metabolic dysfunction and neuroinflammation
par: Renata Spezani, et autres
Publié: (2025)

Safety and efficacy of glucagon‐like peptide‐1 (GLP‐1) receptor agonists in patients with weight regain or insufficient weight loss after metabolic bariatric surgery: A systematic review and meta‐analysis
par: Ali Esparham, et autres
Publié: (2024)

The safety, tolerability, pharmacokinetics and pharmacodynamics of an optimized dual GLP ‐1/ GIP receptor agonist ( BGM0504 ) in healthy volunteers: A dose‐escalation Phase I study
par: Yuxin Fan, et autres
Publié: (2025)

GLP ‐1 receptor agonists for treating obesity without diabetes: A systematic review and meta‐analysis of economic evaluations
par: Teerapon Dhippayom, et autres
Publié: (2025)

Cardiovascular and kidney outcomes of GLP ‐1 receptor agonists in adults with obesity: A target trial emulation study
par: Huilin Tang, et autres
Publié: (2025)

Effectiveness and safety of GLP ‐1 receptor agonists in craniopharyngioma patients with obesity: A multicentre real‐world study
par: Flora Lambert, et autres
Publié: (2025)

Real‐world persistence and dose titration of GLP ‐1 receptor agonists in type 2 diabetes: A UK population‐based cohort study by obesity and cardiovascular disease status
par: Franziska S. Ulrich, et autres
Publié: (2026)

Potential role of glucagon like peptide (GLP)‐1 receptor agonist to reduce risk of colorectal cancer?
par: Iskandar Idris
Publié: (2024)

Evaluating appetite/satiety hormones and eating behaviours as predictors of weight loss maintenance with GLP‐1RA therapy in adolescents with severe obesity
par: Megan O. Bensignor, et autres
Publié: (2024)

Adherence to GLP ‐1 receptor agonists and SGLT2 inhibitors by out‐of‐pocket spending among Medicare beneficiaries with diabetes
par: Nicklas S. Klepser, et autres
Publié: (2025)

The NLRP3 inhibitor NT‐0796 enhances and sustains GLP‐1R agonist‐mediated weight loss in a murine diet‐induced obesity model
par: Peter Thornton, et autres
Publié: (2025)

Sex differences in the efficacy of GLP ‐1 receptor agonists: A systematic review and meta‐analysis of cardiovascular and renal outcome trials
par: Hasan Fareed Siddiqui, et autres
Publié: (2025)

Effects of GLP ‐1 receptor agonists on incidence and outcomes of ischemic stroke and myocardial infarction: A systematic review and meta‐analysis
par: Nawal Alammari, et autres
Publié: (2025)

Glucagon‐like peptide 1 ( GLP ‐1) receptor agonists' use during pregnancy: Safety data from regulatory clinical trials
par: Claire H. Parker, et autres
Publié: (2025)

Phase I study of the oral GLP ‐1 receptor agonist DA ‐ 302168S : Safety, pharmacokinetics, and pharmacodynamics in healthy and overweight/obese adults
par: Liang Zheng, et autres
Publié: (2025)

Association of GLP1 ‐receptor agonist use with liver disease progression, major cardiovascular events, and mortality in people with hepatic steatosis and diabetes
par: Suleiman Al Ashi, et autres
Publié: (2025)

The effect of GLP ‐1 receptor agonists on circulating inflammatory markers in type 2 diabetes patients: A systematic review and meta‐analysis
par: Yifan Ren, et autres
Publié: (2025)

No causal link between the supply of GLP ‐1 receptor agonists and antidepressants: Real‐world evidence from the Australian Pharmaceutical Benefits Scheme
par: Osvaldo P. Almeida, et autres
Publié: (2025)

The importance of treatment sequencing with SGLT2 inhibitors and GLP ‐1 receptor agonists combination for kidney function preservation in type 2 diabetes
par: Mario Luca Morieri, et autres
Publié: (2026)

Glucagon‐like peptide‐1 receptor agonists and upper endoscopy: a real‐world experience
par: Pichamol Jirapinyo, et autres
Publié: (2025)

Efficacy and safety of GLP ‐1 receptor agonists and SGLT2 inhibitors as adjuncts to insulin in type 1 diabetes: Systematic review and meta‐analysis
par: Sama M. Abdel‐Rahman, et autres
Publié: (2026)

One‐year usage patterns of SGLT ‐2 inhibitors and GLP ‐1 receptor agonists in individuals with type 2 diabetes in a real‐world population
par: Louise A. Donnelly, et autres
Publié: (2025)

Effectiveness of add‐on therapy with SGLT2 inhibitors or GLP ‐1 receptor agonists in adults with type 1 diabetes: A prospective DPV registry study
par: Christina Baechle, et autres
Publié: (2024)

Glucagon‐like peptide ‐1 receptor agonist ‐based agents and weight loss composition: Filling the gaps
par: Robert L. Dubin, et autres
Publié: (2024)

Hepatic GCGR is required for the superior weight loss and metabolic effects of a structurally related analogue of the dual GCGR / GLP ‐ 1R agonist survodutide in mice
par: Fen Long, et autres
Publié: (2025)

Long‐term delirium and survival outcomes in patients treated with GLP ‐1 receptor agonists versus metformin in type 2 diabetes: A population‐based cohort study
par: Mingyang Sun, et autres
Publié: (2025)

Efficacy of GLP ‐1 receptor agonists in patients with obesity and heart failure with preserved ejection fraction: A systematic review and meta‐analysis of randomised controlled trials
par: Armando Talavera, et autres
Publié: (2025)

Binding kinetics, bias, receptor internalization and effects on insulin secretion in vitro and in vivo of a novel GLP ‐ 1R / GIPR dual agonist, HISHS ‐2001
par: Yusman Manchanda, et autres
Publié: (2025)